TISCH CANCER INSTITUTE AT THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Principal Investigator/Director: Ramon Parsons, MD, PhD ABSTRACT: The mission of the Tisch Cancer Institute is to advance basic, clinical and population health cancer research, so as to prevent cancer in healthy individuals and improve the lives of cancer patients and their families in our diverse communities. To accomplish this mission, the TCI has developed collaborative research programs that strive to translate discoveries to new therapies and to develop new prevention and delivery strategies with priority given to cancers affecting our catchment area. TCI?s four cancer research programs are: Cancer Immunology, Cancer Mechanisms, Cancer Prevention and Control, and Cancer Clinical Investigation. Within its four programs, the TCI has a strong foundation of cancer research with direct cancer-related funding of $53,106,982. This includes peer-reviewed funding of $36,910,750, of which $27,662,959 is NIH funding, including $15,939,357 from the NCI. The TCI fosters intra and inter-programmatic cancer research through strategic planning, pilot project awards, interdisciplinary meetings and retreats, and disease-specific focus groups. In addition, the TCI enables cutting-edge research by providing outstanding cores, equipment, facilities and information technology. TCI supports the following five shared resources: Flow Cytometry, Mouse Genetics, Microscopy, Biostatistics, and Human Immune Monitoring Center, as well as the following three cores-in- development: Biorepository and Pathology Core, Bioinformatics for Next Generation Sequencing, and Biomedical Data Science and Informatics. The Cancer Clinical Trials Office with its newly established Early Phase Trials Unit provides the infrastructure to conduct novel, investigator initiated protocols developed by TCI investigators. The TCI?s catchment area includes the New York City (NYC) neighborhoods of East Harlem, Central Harlem and the Upper East Side, with the Harlems experiencing excess cancer incidence, morbidity and mortality as compared to NYC and the US. In addition, the TCI is the coordinating center for the World Trade Center First Responders Program, and the rescue workers affected by the 9/11 attacks form a distinct and unique component of the TCI catchment area. TCI develops and fosters a dynamic team of scientists, clinical investigators and administrators and provides the research infrastructure support needed to spur new cancer discoveries and improve the outcomes of cancer patients and their families.

Public Health Relevance

TISCH CANCER INSTITUTE AT THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Principal Investigator/Director: Ramon Parsons, MD, PhD Public Health Relevance Statement: The Tisch Cancer Institute provides an infrastructure to advance basic, clinical and population health cancer research, so as to prevent cancer in healthy individuals and improve the lives of cancer patients and their families in our diverse communities. To accomplish this mission, the TCI has developed collaborative research programs that strive to translate discoveries to new therapies and to develop new prevention and delivery strategies with priority given to cancers affecting our catchment area. The Cancer Clinical Trials Office with its newly established Early Phase Trials Unit provides the infrastructure to conduct novel, investigator initiated protocols developed by TCI investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA196521-06
Application #
10022654
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2015-08-01
Project End
2025-07-31
Budget Start
2020-08-11
Budget End
2021-07-31
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Labgaa, Ismail; Villacorta-Martin, Carlos; D'Avola, Delia et al. (2018) A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 37:3740-3752
Mascarenhas, J; Virtgaym, E; Stal, M et al. (2018) Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study. Ann Hematol 97:1369-1374
Wu, Lisa M; Amidi, Ali; Valdimarsdottir, Heiddis et al. (2018) The Effect of Systematic Light Exposure on Sleep in a Mixed Group of Fatigued Cancer Survivors. J Clin Sleep Med 14:31-39
Miller, Albert; Szeinuk, Jaime; Noonan, Curtis W et al. (2018) Libby Amphibole Disease: Pulmonary Function and CT Abnormalities in Vermiculite Miners. J Occup Environ Med 60:167-173
Vuong, Linh T; Iomini, Carlo; Balmer, Sophie et al. (2018) Kinesin-2 and IFT-A act as a complex promoting nuclear localization of ?-catenin during Wnt signalling. Nat Commun 9:5304
Bickell, Nina A; Lin, Jenny J; Abramson, Sarah R et al. (2018) Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers. J Oncol Pract 14:e23-e33
Li, Weiqiang; Middha, Mridu; Bicak, Mesude et al. (2018) Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. Eur Urol 74:710-719
Nobre, Ana Rita; Entenberg, David; Wang, Yarong et al. (2018) The Different Routes to Metastasis via Hypoxia-Regulated Programs. Trends Cell Biol 28:941-956
Zhang, Maomao; Di Martino, Julie S; Bowman, Robert L et al. (2018) Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. Cancer Discov 8:1006-1025
Leiter, Amanda; Bickell, Nina A; LeRoith, Derek et al. (2018) Statin Use and Breast Cancer Prognosis in Black and White Women. Horm Cancer 9:55-61

Showing the most recent 10 out of 143 publications